LAVA THERAPEUTICS NV

LAVA Therapeutics NV is a clinical-stage biotechnology company developing bispecific gamma-delta T cell engagers for cancer treatment. Its primary business model involves preclinical and clinical research that relies on animal testing. The company's lead drug candidates, such as LAVA-051 and LAVA-1207, are developed using animal models to assess efficacy and safety, a standard but exclusionary practice in biopharmaceutical development. This places its core research and development activities within the scope of commercial animal exploitation.

The evidence gathered from sources related to animal experimentation frameworks, such as the abstracts from the 14th FELASA congress, underscores the industry context in which LAVA Therapeutics operates, where animal use is integral to drug development pipelines. While specific violation details or penalty amounts for LAVA Therapeutics are not provided in the gathered evidence, the company's business model is fundamentally reliant on the use of laboratory animals for research. No public commitment to phasing out animal testing or adopting alternative testing methods was identified in the available information.